Pharmacovigilance of over-the-counter products based in community pharmacy: Methodological issues from pilot work conducted in Hampshire and Grampian, UK

Pharmacoepidemiology and Drug Safety

Volumn 11, Issue 6, 2002, Pages 503-513

  Layton, D ^a   Sinclair, H K ^b   Bond, C M ^b   Hannaford, P C ^b   Shakir, S A W ^a,c  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Ibuprofen; Non prescription medicines; Pharmacists; Pharmacovigilance

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; COUMARIN DERIVATIVE; CYTOTOXIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IBUPROFEN; LITHIUM; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; QUINOLONE DERIVATIVE;

ADULT; AGE; ARTICLE; ASTHMA; CENTRAL NERVOUS SYSTEM DISEASE; CIGARETTE SMOKING; CLINICAL OBSERVATION; COHORT ANALYSIS; COMMUNITY; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG USE; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH CARE UTILIZATION; HUMAN; INGESTION; LICENSING; MALE; METHODOLOGY; NONBIOLOGICAL MODEL; OUTCOMES RESEARCH; PEPTIC ULCER; PHARMACIST; PHARMACY; PILOT STUDY; PREVALENCE; PRIORITY JOURNAL; PURCHASING; QUESTIONNAIRE; SOCIAL STATUS; STOMACH ULCER; SYMPTOMATOLOGY; UNITED KINGDOM;

ADULT; AGE FACTORS; COHORT STUDIES; DRUG INTERACTIONS; DRUG UTILIZATION REVIEW; DRUGS, NON-PRESCRIPTION; ENGLAND; FEMALE; HUMANS; IBUPROFEN; INCIDENCE; MALE; MIDDLE AGED; PHARMACIES; PILOT PROJECTS; PRODUCT SURVEILLANCE, POSTMARKETING; QUESTIONNAIRES; SMOKING;

EID: 0036750065     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.734     Document Type: Article

References (37)

1. World Health Organization (WHO) Guidelines for National Drugs Policies. WHO: Geneva, 1995.
2. Anon. Outline of the envisaged proposals of the European Commission for the review of community pharmaceutical legislation. 23 January 2001. The Changing OTC Market. Management Forum, Guildford.
3. European Community. Directive for Medicines Classification. 92/96/EEC.
4. Schmid B. The safety assessment of over-the-counter products. Arch Toxicol 1995; 17: 305-311.
5. Biscarini L. Anti-inflammatory analgesics and drugs used in gout. In Meyler's Side Effects of Drugs (12th edn), Dukes MNG (ed.). Elsevier: Amsterdam 1992; chapter 10.
6. Mandell BF. General tolerability and use of nonsteroidal anti-inflammatory drugs. Am J Med 1999; 107: 72S-77S.
7. Henry D, Lim LL-Y, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual nonsteroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 312: 1563-1566.
8. Moore N, Ganse EV, Le Parc JM, et al. The Pain Study: Paracetamol, Aspirin and Ibuprofen New Tolerability Study. Clin Drug Invest 1999; 18: 89-98.
9. Committee on Safety of Medicines and the Medicines Control Agency. Terfendine: now only available on prescription. Curr prob Pharmacovigilance 1997; 23: 1.
10. )): a cautionary tale from Glasgow. Addiction 1999; 94: 1575-1577.
11. Downie G, Hind C, Kettle J. The abuse and misuse of prescribed and over-the-counter medicines. Hosp Pharmacist 2000; 7: 242-250.
12. RPSGB. Potential Candidates for reclassification from POM to P. website:http://www.rpsgb.org.uk/pdfs/pomtopreclasslist.pdf[2 April 2002].
13. British Market Research Bureau. Everyday Healthcare: A Consumer Study of Self-medication in Great Britain. BRMB: London; 1987.
14. Livingstone CR, Pugh AL, Winn S, Williamson VK. Developing community pharmacy services wanted by local people: information and advice about prescription medicines. Int J Pharmacy Pract 1996; 4: 94-102.
15. Rivers G, Rutter PM, Jones IF. Purchasing General Sales List Medicines (GSL): a comparison on the level of advice given by pharmacy and non-pharmacy outlets. Pharm J 1998; 261: R28.
16. Sinclair HK, Bond CM, Hannaford PC. Pharmacovigilance of over-the-counter products based in community pharmacy: a feasible option? Pharmacoepidemiol Drug Safe 1999; 8: 479-491.
17. Carstairs V, Morris R. Deprivation and Health in Scotland. Aberdeen University Press: Aberdeen, 1991; 305-317.
18. Carstairs V, Morris R. Deprivation and health in Scotland. Health Bull 1990; 48: 162-175.
19. British National Formulary (40th edn). British Medical Association and the Royal Pharmaceutical Society of Great Britain, Pharmaceutical Press: London, 2000.
20. Shaw JP, Gauld NJ, Emmerton LM, Tucker IG, Pethicas BD. Usage of diclofenac potassium (Catflam) when purchased as a non-prescription medicine in New Zealand. J Soc Admin Pharmacy 2000; 17: 169-175.
21. 2-antagonists. Pharm J 1996; 256: 593-596.
22. Anon. A new age for pharmacy practice research: promoting evidence-based practice in pharmacy. Report of the Pharmacy Practice R&D task force. Royal Pharmaceutical Society of Great Britain, 1997.
23. Krska J, Kennedy EJ, Hansford D, John DN. Pharmacists' opinions on their involvement in a community pharmacy based practice research study. Pharm J 1998; 261: R54.
24. Kennedy E, Krska J, John D, Hansford D. Effect of incentives on recruitment and response rate in a community-based pharmacy practice study. Int J Pharm Pract 1999; 7: 80-85.
25. Grewar J, Matthews J, McMahon AD, Macdonald TM. Capturing data on over-the-counter medicines in community pharmacies: a methodological study. Pharm J 1997; 259: 736-739.
26. Grewar J, MacDonald TM. Hay fever symptoms and over-the-counter remedies: a community pharmacy study. Int J Pharm Pract 1998; 6: 22-29.
27. Sihvo S, Klaukka T, Martinkainen J, Hemminki E. Pharmacoepidemiology and prescription. Frequency of daily over-the-counter drug use and potentially clinically significant over-the-counter-prescription drug interactions in the Finnish adult population. Eur J Clin Pharm 2000; 56: 495-499.
28. Bajekal M. Use of health services and prescribed medicines. In Health Survey for England: Cardiovascular Disease 1998. The Stationary Office, Department of Health: London, 1998; chapter 7.
29. Sinclair HK, Bond CM, Hannaford PC. Long term follow-up studies of users of non-prescription medicines purchased from community pharmacies. Some methodological issues. Drug Safety 2001; 24: 929-938.
30. Gastrointestinal and liver diseases. In Pathology and Therapeutics for Pharmacists (2nd edn), Greene RJ, Harris ND (eds). Pharmaceutical Press: London, 2000; chapter 6.
31. Mann RD, Rawlins MD, Fletcher P. Age and the spontaneous reporting of adverse reactions in the United Kingdom. Pharmacoepidemiol Drug Safe 1992; 1: 19-23.
32. Gutthann SP, Garcia Rodriguez AL, Raiford DS. Individual non-steroidal anti-inflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997; 8: 18-24.
33. Honig PK, Gillespie BK. Drug interactions between prescribed and over-the-counter medication. Drug Safety 1995; 13: 296-303.
34. Honig PK, Gillespie BK. Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs. Clin Pharmacokinetics 1998; 35: 167-171.
35. Committee on Safety of Medicines and the Medicines Control Agency. Reporting of suspected adverse drug reactions by pharmacists. Current Problems in Pharmacovigilance. November 1999.
36. Thomas DHV, Noyce PR. Over the counter drugs. The interface between self medication and the NHS. BMJ 1996; 312:688-691.
37. Anon. Population Risk Trials: A New OTC Switch Strategy. PEGUS Research INC: Salt Lake City, USA Communication). website: http://www.pegus.com/prt/default.htm [Accessed 05/09/2000].